Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer
Open Access
- 7 March 2006
- journal article
- Published by Wiley in Cancer Science
- Vol. 97 (3), 192-198
- https://doi.org/10.1111/j.1349-7006.2006.00164.x
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Gefitinib (“Iressa”, ZD1839), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses Breast Cancer Resistance Protein/ABCG2–Mediated Drug ResistanceCancer Research, 2005
- Phytoestrogens/Flavonoids Reverse Breast Cancer Resistance Protein/ABCG2-Mediated Multidrug ResistanceCancer Research, 2004
- Carboxylesterase-Mediated Sensitization of Human Tumor Cells to CPT-11 Cannot Override ABCG2-Mediated Drug ResistanceMolecular Pharmacology, 2003
- Transport of 7-Ethyl-10-hydroxycamptothecin (SN-38) by Breast Cancer Resistance Protein ABCG2 in Human Lung Cancer CellsBiochemical and Biophysical Research Communications, 2001
- Breast Cancer Resistance Protein Directly Confers SN-38 Resistance of Lung Cancer CellsBiochemical and Biophysical Research Communications, 2001
- Expression of Drug Resistance‐related Genes in Head and Neck Squamous Cell Carcinoma and Normal MucosaJapanese Journal of Cancer Research, 2000
- Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.JCI Insight, 1998
- The Role of Glucuronidation in 7‐Ethyl‐10‐hydroxycamptothecin Resistance in vitroJapanese Journal of Cancer Research, 1997
- No Alteration in DNA Topoisomerase I Gene Related to CPT‐11 Resistance in Human Lung CancerJapanese Journal of Cancer Research, 1996
- Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell lineBiochemical and Biophysical Research Communications, 1992